ArticleOpen forum infectious diseases2022
Management of Histoplasmosis by Infectious Disease Physicians.
Article in Open forum infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Delayed diagnosis of primary cutaneous histoplasmosis in a patient receiving tumour necrosis factor alpha inhibitor therapy.BMJ case reports · 2026Article
- A Call to Investigate the Association Between Histoplasmosis and Fatigue.Open forum infectious diseases · 2026Article
- A Case of Native Joint Septic Arthritis Due to Histoplasma Capsulatum in a Patient on Adalimumab.Cureus · 2026Article
- Neoaortoiliac reconstruction for aJournal of vascular surgery cases and innovative techniques · 2026Article
- Review
- Article
- Mapping the Geographic Distribution of Dimorphic Mycoses Using a US Commercial Insurance Database.Open forum infectious diseases · 2025Article
- Endemic Mycoses for Pulmonary Clinicians: From Nodules to ARDS.CHEST pulmonary · 2025Review
- Assessment of Prior Infection With Histoplasmosis Using Skin Test and Serological Surveys: A Global Systematic Review.Open forum infectious diseases · 2025Review
- Radiological features of chronic pulmonary histoplasmosis: Easily mistaken for tuberculosis.PLoS neglected tropical diseases · 2025Review
- Miliary Patterns on Computerized Tomography Imaging of Chest in Immunocompromised Patient: Unveiling Disseminated Histoplasmosis.The American journal of case reports · 2025Article
- Gastric Outlet Obstruction Caused by Histoplasmosis in a Nonendemic Region.ACG case reports journal · 2025Article
- Disseminated Histoplasmosis With Lung and Liver Involvement in an Immunocompetent Patient.Cureus · 2024Article
- Disseminated Histoplasmosis Diagnosed in an Immunocompetent Patient from a Non-Endemic Area: Neglected or Emerging Disease?Diagnostics (Basel, Switzerland) · 2024Article
- Genotypic diversity, virulence, and molecular genetic tools inMicrobiology and molecular biology reviews : MMBR · 2024Review
- Should Histoplasmosis be Screened for Before Initiation of Tumour Necrosis Factor Alpha Inhibitors?European journal of case reports in internal medicine · 2024Article
- Disseminated histoplasmosis in an immunosuppressed patient successfully treated with isavuconazole.BMJ case reports · 2023Article
- Diagnosis and Treatment of Fungal Infections in Lung Transplant Recipients.Pathogens (Basel, Switzerland) · 2023Review
- The Geographic Distribution of Dimorphic Mycoses in the United States for the Modern Era.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Article
- Disseminated Histoplasmosis-Associated Cardiac Tamponade in a Patient With Acquired Immunodeficiency Syndrome.Journal of investigative medicine high impact case reportsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Background: The Infectious Diseases Society of America (IDSA) guidelines for the management of histoplasmosis were last revised 15 years ago. Since those guidelines were compiled, new antifungal treatment options have been developed. Furthermore, the ongoing development of immunomodulatory therapies has increased the population at increased risk to develop histoplasmosis. Methods: An electronic survey about the management practices of histoplasmosis was distributed to the adult infectious disease (ID) physician members of the IDSA's Emerging Infections Network. Results: The survey response rate was 37% (551/1477). Only 46% (253/551) of respondents reported seeing patients with histoplasmosis. Regions considered endemic had 82% (158/193) of physicians report seeing patients with histoplasmosis compared to 27% (95/358) of physicians in regions not classically considered endemic ( Conclusions: Though there are increased reports of histoplasmosis diagnoses outside regions classically considered endemic, a majority of ID physicians reported not seeing patients with histoplasmosis. Most respondents reported adherence to IDSA guidelines recommending itraconazole in each clinical situation. New histoplasmosis guidelines need to reflect the growing need for updated general guidance, particularly for immunocompromised populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.